Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 109,812,240
  • Shares Outstanding, K 2,443,530
  • Annual Sales, $ 16,967 M
  • Annual Income, $ 5,792 M
  • 36-Month Beta 0.76
  • Price/Sales 6.44
  • Price/Cash Flow 17.40
  • Price/Book 14.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.60
  • Number of Estimates 1
  • High Estimate 0.60
  • Low Estimate 0.60
  • Prior Year 0.53
  • Growth Rate Est. (year over year) +13.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.59 +7.09%
on 10/25/18
45.10 -1.24%
on 11/09/18
+2.01 (+4.73%)
since 10/12/18
3-Month
41.23 +8.03%
on 10/11/18
49.98 -10.88%
on 08/29/18
-2.33 (-4.97%)
since 08/10/18
52-Week
41.23 +8.03%
on 10/11/18
58.37 -23.69%
on 01/23/18
-5.37 (-10.76%)
since 11/10/17

Most Recent Stories

More News
EVOTEC AG REPORTS FIRST NINE-MONTH 2018 RESULTS AND CORPORATE UPDATES

NVO : 44.54 (-0.89%)
NVS : 88.23 (-1.11%)
CELGZ : 0.95 (+4.40%)
Asterias Biotherapeutics Reports Third Quarter Results

Clinical Programs Continue to Progress

AST : 1.25 (-3.85%)
NVO : 44.54 (-0.89%)
BTX : 1.68 (-12.50%)
Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director

Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its proprietary technology platform, announced today that it has appointed...

NVO : 44.54 (-0.89%)
Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales

Novo Nordisk (NVO) reports in line earnings in the third quarter of 2018 and announces restructuring plans.

NVO : 44.54 (-0.89%)
MRK : 74.69 (-0.23%)
LLY : 113.20 (+0.88%)
BMY : 52.85 (-1.01%)
China Repaglinide (Novo Nordisk & Boehringer Ingelheim) Market, 2018-2022

The "Investigation Report on China's Repaglinide Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

NVO : 44.54 (-0.89%)
Aeterna Zentaris Soars on Macrilen(TM) Out Licensing Deal, Analysts Review and Target

NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

AEZS : 2.41 (+6.64%)
NVO : 44.54 (-0.89%)
SBBP : 5.24 (-9.97%)
Aeterna Zentaris Announces Novo Nordisk to acquire rights to Macrilen(TM) in United States and Canada

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) announces that it was advised yesterday that Strongbridge BioPharma Plc has signed an agreement with Novo Nordisk A/S pursuant to which Novo Nordisk will...

AEZS.TO : 3.20 (+7.74%)
AEZS : 2.41 (+6.64%)
NVO : 44.54 (-0.89%)
SBBP : 5.24 (-9.97%)
Today's Research Reports on Stocks to Watch: Aeterna Zentaris and AbbVie

NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Aeterna Zentaris saw its shares climbing as Wall Street learned about Novo Nordisk and Strongbridge Biopharma's deal where Aeterna Zentaris stands to capitalize....

AEZS : 2.41 (+6.64%)
NVO : 44.54 (-0.89%)
Novo Nordisk: 3Q Earnings Snapshot

BAGSVAERD, Denmark (AP) _ Novo Nordisk A/S (NVO) on Thursday reported third-quarter earnings of $1.4 billion.

NVO : 44.54 (-0.89%)
Novo Nordisk's operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies in the first nine months of 2018

Sales decreased by 2% in Danish kroner and increased by 4% in local currencies to DKK 82.1 billion.

NVO : 44.54 (-0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade NVO with:

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 45.08
1st Resistance Point 44.81
Last Price 44.54
1st Support Level 44.38
2nd Support Level 44.21

See More

52-Week High 58.37
Fibonacci 61.8% 51.82
Fibonacci 50% 49.80
Fibonacci 38.2% 47.78
Last Price 44.54
52-Week Low 41.23

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar